Számháború és a tények a hepatitis C pegilált interferon alapú kezelésében

Translated title of the contribution: "War of numbers" and the facts about pegylated interferon based treatment of chronic hepatitis C

Makara Mihály, Hunyady Béla

Research output: Contribution to journalArticle


Further to the traditional pegylated interferon and ribavirin products, used since 2001 in the treatment of chronic hepatitis C, two new direct antiviral protease inhibitors were licensed in 2011: telaprevir and boceprevir. Added to the traditional dual combination either of these drugs increase significantly the rate of sustained viral response. Discussions over the relative efficacy of two different bands of interferons with different pharmacokinetic properties as well as of the different protease inhibitors are arising regularly. After critical review of the relevant literature the authors did not identify any clinically meaningful differences in efficacy of the two pegylated interferons (a 2a or a 2b) neither in dual nor in triple combination therapies. There has been no convincing evidence found to support superiority of one protease inhibitor over the other, either: Generally both drugs can be recommended for patients previously or actually not responding to dual therapy. However, there is a tendency towards a potential difference between the relapse rates after treatments with the two pegylated interferons in dual therapy, attributable potentially to the difference of their pharmacokinetic profiles. In special cases the choice of protease inhibitors can be influenced by cost-effectiveness and side effect profile.

Original languageHungarian
Pages (from-to)336-343
Number of pages8
JournalLege Artis Medicinae
Issue number7-8
Publication statusPublished - Oct 18 2013


ASJC Scopus subject areas

  • Medicine(all)

Cite this